Synapse - Augmenting CAR T-cell functions with LIGHT

Augmenting CAR T-cell functions with LIGHT Journal Article

Authors:	Cai, W.; Tanaka, K.; Mi, X.; Rajasekhar, V. K.; Khan, J. F.; Yoo, S.; de Stanchina, E.; Rahman, J.; Mathew, S.; Abrahimi, P.; Souness, S.; Purdon, T. J.; McDowell, J. R.; Meyerberg, J.; Fujino, T.; Healey, J. H.; Abdel-Wahab, O.; Scheinberg, D. A.; Brentjens, R. J.; Daniyan, A. F.
Article Title:	Augmenting CAR T-cell functions with LIGHT
Abstract:	Chimeric antigen receptor (CAR) T-cell therapy has resulted cytotoxicity mediated by the CAR and antigen-independent in remarkable clinical success in the treatment of B-cell ma- killing mediated through the interaction of LIGHT with lignancies. However, its clinical efficacy in solid tumors is lymphotoxin-β receptor on cancer cells. Moreover, CAR T cells limited, primarily by target antigen heterogeneity. To overcome expressing LIGHT had immunostimulatory properties that antigen heterogeneity, we developed CAR T cells that over- improved the cells’ proliferation and cytolytic profile. These express LIGHT, a ligand of both lymphotoxin-β receptor on data indicate that LIGHT-expressing CAR T cells may provide a cancer cells and herpes virus entry mediator on immune cells. way to eliminate antigen-negative tumor cells to prevent LIGHT-expressing CAR T cells displayed both antigen-directed antigen-negative disease relapse. ► ©2024 American Association for Cancer Research.
Keywords:	genetics; neoplasm; neoplasms; t lymphocyte; t-lymphocytes; mouse; animal; metabolism; animals; mice; drug screening; xenograft model antitumor assays; cell line, tumor; tumor antigen; immunology; antigens, neoplasm; tumor cell line; chimeric antigen receptor; cytotoxicity, immunologic; therapy; adoptive immunotherapy; immunotherapy, adoptive; procedures; immunocytotoxicity; lymphotoxin beta receptor; humans; human; tumor necrosis factor ligand superfamily member 14; receptors, chimeric antigen; herpesvirus entry mediator ligand
Journal Title:	Cancer Immunology Research
Volume:	12
Issue:	10
ISSN:	2326-6066
Publisher:	American Association for Cancer Research
Date Published:	2024-10-01
Start Page:	1361
End Page:	1379
Language:	English
DOI:	10.1158/2326-6066.Cir-24-0246
PUBMED:	38959337
PROVIDER:	scopus
PMCID:	PMC11444887
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85205525533&doi=10.1158%2f2326-6066.CIR-24-0246&partnerID=40&md5=073e855c14740727006bc16ed0203380
Notes:	Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is David Scheinberg -- MSK author Rajasekhar Vinagolu's first and last names are swapped on the original publication -- Source: Scopus